Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Cystic fibrosis (CF) is a progressive genetic disease that adversely affects a person's lungs, pancreas and other vital organs, says Dr. Michael Boyle, president and CEO of the Cystic Fibrosis ...
2don MSN
Findings from a new Dartmouth-led study, published in the journal mBio, highlight key differences in the gut microbiome ...
The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...
Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback